Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)Cristina Astrid Tentori, Najla H. Al Ali, Saverio D’Amico et al.|Blood|2023Cited by 5
Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)Marta Peña, Alberto Mussetti, Giulia Losi et al.|Blood|2024Cited by 2
Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysisJacopo Mariotti, Stéfania Bramanti, Chiara Pinton et al.|British Journal of Haematology|2025Cited by 1
Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific AntibodiesGiulia Losi, Alberto Mussetti, Marta Peña et al.|Blood|2024Cited by 0